Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
NCT01688882 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2016-04-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was stopped after Part 1 completed and was terminated because the predefined criteria of efficacy was not reached ( \>50% better then placebo)” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-04-25Results posted on the registry: Novartis Pharmaceuticals, QGE031 (NCT02075008)
- 2017-04-07Results posted on the registry: Novartis Pharmaceuticals, QGE031 + Placebo (NCT02336425)
- 2017-04-04Results posted on the registry: Johns Hopkins University, omalizumab + placebo (NCT00604786)
- 2017-03-29Also stopped (withdrawn): National Jewish Health, Omalizumab (Xolair) + Placebo (NCT00851370)
- 2017-03-08Results posted on the registry: Novartis Pharmaceuticals, QGE031 + Omalizumab (NCT01716754)
- 2016-09-20Results posted on the registry: Novartis Pharmaceuticals, Omalizumab (NCT02329223)
- 2016-04-06Results posted on the registry: Hugh A Sampson, MD, Placebo for omalizumab + Omalizumab (NCT01157117)
- 2016-02-15Results posted on the registry: Charite University, Berlin, Germany, Omalizumab + Omalizumab (NCT01580592)
- 2016-01-18Results posted on the registry: Charite University, Berlin, Germany, Omalizumab + Omalizumab (NCT02169115)
- 2015-09-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Omalizumab + Inhaled Corticosteroid Boost Therapy (ICS) (NCT01430403)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision